Significance of Postoperative Acute Renal Failure After Continuous-Flow Left Ventricular Assist Device Implantation
|
|
- Emery Fletcher
- 6 years ago
- Views:
Transcription
1 Significance of Postoperative Acute Renal Failure After Continuous-Flow Left Ventricular Assist Device Implantation Jamil Borgi, MD, Athanasios Tsiouris, MD, Arielle Hodari, MD, Chad M. Cogan, MS, Gaetano Paone, MD, and Jeffrey A. Morgan, MD Department of Surgery, Division of Cardiothoracic Surgery, Henry Ford Hospital, Heart and Vascular Institute, Detroit, Michigan Background. Deteriorating renal function is common in patients with advanced heart failure and is associated with poor outcomes. The relationship between renal function and left ventricular assist device (LVAD) implantation is complex and has been explored in multiple studies with contradictory results. The aim of our study is to examine the significance of postoperative renal failure after implantation of a continuous-flow LVAD and its relationship to outcomes. Methods. From March 2006 to July 2011, 100 patients underwent implantation of a HeartMate II (Thoratec Corp, Pleasanton, CA) or HeartWare (Heart International, Inc, Framingham, MA) LVAD at our institution. Patients were stratified based on postoperative development of acute renal failure (ARF). Variables were compared using 2-sided t tests, 2 tests, Cox proportional hazards models, and log-rank tests to determine whether there was a difference between the 2 groups and whether postoperative renal failure was a significant independent predictor of outcome. Results. We identified 28 patients (28%) with postoperative ARF and 72 patients (72%) without postoperative ARF. The 2 groups were similar with regard to demographics and comorbidities. The patients with ARF were more likely to be intubated preoperatively (14.3% versus 1.4%; p 0.021) and had higher preoperative central venous pressure (CVP) (14.3 mm Hg versus 10.7 mm Hg; p 0.015). Postoperatively patients with ARF had a longer hospital stay (32.4 versus 18.7; p 0.05), were more likely to experience right ventricular (RV) failure (25% versus 5.6%; p 0.01) and ventilator-dependent respiratory failure (VDRF) (28.6% versus 6.9%; p 0.007). There was a significant difference when comparing the ARF and non-arf groups for 30-day (17.9% versus 0%; p < 0.001), 180-day (28.6% versus 2.8%; p < 0.001), and 360- day mortality (28.6% versus 6.9%; p 0.012). Conclusions. Patients in whom ARF developed after LVAD implantation had a higher rate of VDRF and RV failure and a longer length of stay (LOS). Postoperative ARF was associated with higher mortality at the 30-day, 180-day, and 360-day intervals. ARF after LVAD may be an early marker of poor outcome, particularly RV failure, and may be an opportunity for early intervention and rescue. (Ann Thorac Surg 2013;95:163 9) 2013 by The Society of Thoracic Surgeons Congestive heart failure continues to be a major medical problem reaching epidemic proportions with approximately 400,000 newly diagnosed patients per year in the United States alone and 500,000 patients with end-stage heart failure refractory to medical treatment [1]. Left ventricular assist device (LVAD) implantation has been used as a bridge to transplantation (BTT) in patients with end-stage heart failure, with proven benefit. Its use is also gaining acceptance with growing evidence as destination therapy (DT) for patients who are deemed not eligible for cardiac transplantation. Superiority of mechanical circulatory support versus best medical management is now widely accepted [2]. Improvement in technology, along with expanding experience in implantation and management of VADs, has resulted in improved complication profiles. Applicability and outcomes have been shown to improve Accepted for publication Aug 27, Address correspondence to Dr Borgi, Department of General Surgery, 2799 W Grand Blvd, Detroit, MI 48202; jamil.borgi@gmail.com. with the introduction of new-generation continuousflow LVADs with axial pumps (Heartmate II, Thoratec Corp, Pleasanton, CA; Jarvik 2000, Jarvik Heart Inc, New York, NY; Debakey VAD, MicroMed Cardiovascular, Inc, Houston, TX) and centrifugal pumps (Heart- Ware HVAD, HeartWare International, Inc, Framingham, MA; DuraHeart, Terumo Heart, Inc, Ann Arbor, MI) [3]. Deteriorating renal function is common in patients with advanced heart failure and is associated with poor outcomes [4 6]. The relationship between renal function and LVADs is complex and has been explored in multiple studies with contradictory results [7 15]. Poor renal function was associated with poor outcomes after LVAD implantation [7, 9, 10, 14, 15]. Conversely, renal function may improve with LVAD therapy [7 15]. In this study, we sought to assess the effect of acute renal failure (ARF) after LVAD implantation on postoperative morbidity as well as its effect on short-term and long-term survival by The Society of Thoracic Surgeons /$36.00 Published by Elsevier Inc
2 164 BORGI ET AL Ann Thorac Surg POSTOPERATIVE ARF AFTER LVAD IMPLANTATION 2013;95:163 9 Patients and Methods Our health system s institutional review board approved this retrospective study. Between March 2006 and July 2011, 100 patients with end-stage heart failure underwent implantation of LVADs at our hospital, a 1,000-bed quaternary care center. The devices were either Heartmate II (Thoratec Corp) or HeartWare (HeartWare International, Inc) LVADs. Procedures were performed by 3 different surgeons. The patient population was divided into 2 cohorts: those in whom ARF developed (n 28) and those in whom ARF did not develop (n 72). We defined patients with acute renal failure (ARF) as those patients who experienced acute renal injury stage II and greater based on the RIFLE (Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease) criteria [16]: glomerular filtration rate decrease greater than 50% or doubling of the creatinine level. Patient Data Patient demographics included age, sex, race, body surface area (BSA), body mass index (BMI), previous sternotomy, days in hospital before LVAD implantation, preoperative creatinine level, liver function test results, cause (ischemic versus nonischemic cardiomyopathy), and associated comorbidities: hypertension (HTN), diabetes mellitus (DM), chronic renal insufficiency (CRI), dialysis, chronic obstructive pulmonary disease (COPD), and peripheral vascular disease (PVD). CRI was defined as glomerular filtration rate less than 60 ml/min/m 2. Operative characteristics analyzed were type of device (HeartMate II or Heartware), cardiopulmonary bypass (CPB) time, and indication (BTT or DT). Hemodynamic data collected before and after (at 1 and 6 months) LVAD implantation included central venous pressure (CVP), pulmonary artery pressure (PAP), pulmonary capillary wedge pressure (PCWP), left ventricular ejection fraction (LVEF), cardiac index (CI), LV and RV end-diastolic diameter (LVEDD/RVEDD), and mitral and tricuspid regurgitation (MR/TR). Outcome variables were complications, postoperative mortality (within 30 days of operation), survival at 180 and 360 days, intensive care unit (ICU) length of stay (LOS), and overall LOS, transplantation, reoperation for aortic insufficiency Table 1. Patient Demographics and Comorbidities Patient Characteristics No ARF (n 72) ARF (n 28) Age a Male sex 53 (74.6%) 20 (71.4%) b African American race 41 (58.6%) 19 (67.9%) b BSA a BMI a BTT 48 (66.7%) 20 (71.4%) b DT 24 (33.3%) 8 (28.6%) ICM 26 (36.1%) 8 (28.6%) b NIDCM 46 (63.9%) 20 (71.4%) Comorbidities HTN 64 (88.9%) 23 (82.1%) c DM 32 (44.4%) 13 (46.4%) b CRI 19 (26.4%) 11 (39.3%) b Previous history of dialysis 1 (1.4%) 2 (7.1%) c PVD 7 (9.7%) 4 (14.3%) c Preoperative laboratory values Creatinine a Albumin a AST d ALT d Preoperative characteristics Days in hospital preoperatively d Ventilated preoperatively 1 (1.4%) 4 (14.3%) c CPB time d Previous cardiac operation 22 (30%) 6 (21.4%) c a Probabilities based on 2-sided 2-sample t tests. b Probabilities based on 2 tests. c Probabilities based on Fisher s exact tests. d Probabilities based on 2-sided Wilcoxon rank-sum tests. ALT alanine aminotransferase; ARF acute renal failure; AST aspartate transaminase; BMI body mass index; BSA body surface area; BTT bridge to transplantation; CPB cardiopulmonary bypass; CRI chronic renal insufficiency; DM diabetes mellitus; DT destination therapy; HTN hypertension; ICM ischemic cardiomyopathy; NIDCM nonischemic dilatated cardiomyopathy; PVD peripheral vascular disease; SD standard deviation.
3 Ann Thorac Surg BORGI ET AL 2013;95:163 9 POSTOPERATIVE ARF AFTER LVAD IMPLANTATION (AI), noncardiac surgical procedures performed after LVAD implantation, readmission rates, and cause of death. Complications included repeated sternotomy for bleeding, drive line infections, pocket infections, pneumonia, RV failure, postoperative right VAD (RVAD) implantation, dialysis, ventilator-dependent respiratory failure (VDRF), tracheostomy insertion, hemorrhagic or ischemic stroke, and gastrointestinal bleeding. RV failure was defined as the need for inotropic support for more than 1 week or the need for RVAD support. VDRF was defined as the inability to wean the patient from the ventilator for at least 1 week. 165 Statistical Analysis Patient demographics, operative characteristics, postoperative complications, and hemodynamic data were compared in a univariate analysis. Continuous variables were reported as mean, standard deviation, minimum, and maximum and were compared using 2-sided 2-sample t tests. Alternatively, Wilcoxon rank-sum tests were used if normality could not be assumed. Categorical variables were reported as count and percent and were compared using 2 tests. Alternatively, Fisher s exact tests were used if expected cell counts were not sufficiently large. Thirty-day, 180-day, and 360-day survival rates were compared between ARF and non-arf groups using a log-rank test. Finally, preoperative/operative characteristics were individually placed in separate Cox proportional hazards models with 360-day survival as the outcome. Variables that were significant predictors of survival were then entered into a multiple Cox proportional hazards model on predicting 360-day survival. To adjust for confounding differences, the model also included variables that were significantly associated with renal failure. The model was further restricted to only significant predictors after applying a backward elimination method. Adjusted hazard ratios and 95% confidence intervals for hazard ratios were reported. Tests were considered significant at p values less than All analyses were performed using SAS, version 9.2 (SAS Institute, Cary, NC). Results Univariate Analysis A total of 100 patients who underwent LVAD implantation for BTT or DT were included in our study. After stratifying patients according to the development of postoperative ARF, we identified 28 patients (28%) with ARF and 72 patients (72%) without ARF. The 2 groups were similar when comparing age, sex, race, BSA, and BMI. The prevalence of HTN, DM, CRI, dialysis, COPD, and PVD was equal between the 2 groups. BTT constituted 66.7 % of the non-arf group and 71.4% of the ARF group (p 0.647). The cause of heart failure was also found to be similar, with ischemic cardiomyopathy (ICM) constituting 36.1% in the non- Table 2. Postoperative Outcomes Variable No ARF (n 72) ARF (n 28) Transplantation 21 (29.2%) 7 (25.0%) a Postoperative ICU stay b Overall postoperative stay b Reoperation for bleeding 5 (6.9%) 3 (10.7%) c DL infection 6 (8.3%) 0 (0.0%) c Pocket infection 1 (1.4%) 0 (0.0%) c Pneumonia 6 (8.3%) 4 (14.3%) c RV failure after VAD implantation 4 (5.6%) 7 (25.0%) c Postoperative RVAD implantation 0 (0.0%) 5 (17.9%) c Hemodialysis 0 (0.0%) 9 (32.1%) c VDRF 5 (6.9%) 8 (28.6%) c Tracheostomy 1 (1.4%) 2 (7.1%) c Hemorrhagic stroke 7 (9.7%) 2 (7.1%) c Ischemic stroke 7 (9.7%) 2 (7.1%) c Noncardiac operation after VAD 17 (23.6%) 7 (25.0%) a Reoperation for AI 4 (5.6%) 0 (0.0%) c Severe AI 3 (4.2%) 1 (3.6%) c GIB 17 (23.6%) 5 (17.9%) a Readmitted within 30 d after VAD implantation 19 (26.4%) 5 (17.9%) a Postoperative PRBC transfusion b a Probabilities based on 2 tests. b Probabilities based on 2-sided Wilcoxon rank-sum tests. c Probabilities based on Fisher s exact tests. AI aortic insufficiency; ARF acute renal failure; DL drive line; GIB gastrointestinal bleeding; ICU intensive care unit; PRBC packed red blood cells; RV right ventricular; RVAD right ventricular assist device; SD standard deviation; VAD ventricular assist device; VDRF ventilator-dependent respiratory failure.
4 166 BORGI ET AL Ann Thorac Surg POSTOPERATIVE ARF AFTER LVAD IMPLANTATION 2013;95:163 9 Table 3. Preoperative and Postoperative (at 1 and 6 Months) Hemodynamic Data Variable No ARF (n 72) [Min, Med, Max] ARF (n 28) [Min, Med, Max] Preoperative VAD LVEF [5.0, 15.0, 50.0] [5.0, 15.0, 40.0] a Postoperative VAD LVEF (1 mo) [5.0, 15.0, 40.0] [10.0, 20.0, 45.0] a Postoperative VAD LVEF (6 mo) [5.0, 18.0, 75.0] [15.0, 27.5, 70.0] a Preoperative VAD LVEDD [51.0, 74.0, 107.0] [34.0, 65.0, 85.0] a Postoperative VAD LVEDD (1 mo) [20.0, 61.0, 92.0] [34.0, 50.5, 78.0] a Postoperative VAD LVEDD (6 mo) [23.0, 59.0, 109.0] [25.0, 52.0, 87.0] a Preoperative VAD CI [1.0, 1.8, 3.9] [1.3, 1.9, 3.1] a Postoperative VAD CI (1 mo) [1.5, 2.4, 3.8] [1.5, 2.7, 4.9] a Postoperative VAD CI (6 mo) [1.2, 2.3, 3.8] [2.0, 2.4, 3.6] a Preoperative VAD PCWP [6.0, 22.0, 44.0] [12.0, 25.0, 45.0] a Postoperative VAD PCWP (1 mo) [1.0, 10.0, 37.0] [4.0, 8.5, 27.0] a Postoperative VAD PCWP (6 mo) [1.0, 11.0, 21.0] [4.0, 18.0, 26.0] a Preoperative VAD CVP [1.0, 10.0, 27.0] [3.0, 13.5, 27.0] a Postoperative VAD CVP (1 mo) [0, 10.0, 20.0] [3.0, 10.0, 20.0] a Postoperative VAD CVP (6 mo) [0, 6.0, 17.0] [2.0, 9.0, 22.0] a Preoperative VAD PASP [26.0, 50.0, 91.0] [12.0, 56.0, 73.0] a Postoperative VAD PASP (1 mo) [4.0, 33.5, 70.0] [18.0, 40.0, 63.0] a Postoperative VAD PASP (6 mo) [17.0, 36.0, 60.0] [20.0, 36.0, 58.0] a Preoperative VAD RVEDD [8.0, 25.0, 46.0] [12.0, 28.0, 49.0] a Postoperative VAD RVEDD (1 mo) [11.0, 29.0, 49.0] [11.0, 28.0, 49.0] a Postoperative VAD RVEDD (6 mo) [10.0, 29.0, 52.0] [15.0, 23.5, 42.0] a Preoperative VAD MR, moderate/severe 42 (60.9%) 17 (65.4%) b Postoperative VAD MR (1 mo), moderate/severe 14 (21.2%) 2 (8.7%) c Postoperative VAD MR (6 mo), moderate/severe 7 (12.7%) 5 (31.3%) c Preoperative VAD TR, moderate/severe 34 (50.0%) 14 (53.8%) c Postoperative VAD TR (1 mo), moderate/severe 11 (17.5%) 6 (27.3%) c Postoperative VAD TR (6 mo), moderate/severe 9 (16.7%) 5 (33.3%) c a Probabilities based on 2-sided 2-sample t tests. b Probabilities based on 2 tests. c Probabilities based on Fisher s exact tests. ARF acute renal failure; CI cardiac index; CVP central venous pressure; LVEDD left ventricular end-diastolic diameter; LVEF left ventricular ejection fraction; MR mitral regurgitation; PASP pulmonary artery systolic pressure; PCWP pulmonary capillary wedge pressure; RVEDD right ventricular end-diastolic diameter; ST standard deviation; TR tricuspid regurgitation; VAD ventricular assist device. ARF group and 28.6% in the ARF group (p 0.475). Preoperative laboratory values were not found to be statistically different between the 2 groups. Higher preoperative creatinine levels had a larger but nonsignificant trend in the ARF group (1.6 mg/dl versus 1.3 mg/dl; p 0.023). The patients with ARF were more likely to have been ventilated preoperatively (14.3%) compared with the non-arf group (1.4%; p 0.021). Table 1 compares the preoperative demographics and comorbidities between the ARF and non-arf groups. Postoperative outcomes are compared in Table 2. Complications were similar between the non-arf and ARF groups with the exception of ICU stay (9.5 days versus 18.6 days; p 0.005), total LOS (18.7 days versus 32.4 days; p 0.05), need for hemodialysis (0% versus 32.1%; p 0.001), VDRF (6.9% versus 28.6%; p 0.007) and RV failure (5.6% versus 25%; p 0.01). Patients with ARF required more inotropic support, although the difference did not reach statistical significance, with 78% (22/28) requiring inotropic agents after postoperative day 2 compared with 62% (45/72) (p 0.202) of patients in whom renal failure did not develop. Hemodynamic variables are compared in Table 3. Patients with ARF had a higher CVP before VAD implantation (14.3 mm Hg versus 10.7 mm Hg; p 0.015) and a lower LVEDD before VAD implantation (64.6 versus 74.0; p 0.001). All other hemodynamic measurements were comparable between the 2 groups. There was a significant difference when comparing the non-arf and ARF groups for 30-day mortality (0% versus 17.9%; p 0.001), 180-day survival (2.8% versus 28.6%; p 0.001), and 360-day survival (6.9% versus 28.6%; p 0.002) (Fig 1). Of the 28 patients in whom ARF developed, 7% (2/28) died in the early postoperative period before institution of dialysis, 32% (9/28) required hemodialysis, and 68% (17/28) returned to baseline (preoperative level) within 2 weeks of implantation without requiring dialysis. Of the 9 patients who required dialysis, 33% (3/9) died within 1 month of implantation. Four of the remaining 6 patients
5 Ann Thorac Surg BORGI ET AL 2013;95:163 9 POSTOPERATIVE ARF AFTER LVAD IMPLANTATION Table 5. Multivariable Analysis: Adjusted Predictors of 360- Day Survival (N 100) Characteristic Hazards Ratio 95% Confidence Interval for Hazard Ratio 167 Overall ARF , CRI , ARF acute renal failure; CRI chronic renal insufficiency. Fig 1. Kaplan-Meier curve comparing outcomes between acute renal failure (ARF) after left ventricular device (LVAD) implantation and patients without ARF. were free of dialysis within 1 month of implantation. Two patients (7% of patients with ARF and 2% of the total cohort) required permanent renal replacement therapy, with 1 patient dying within 6 months of implantation. For the patients in whom ARF did not develop, causes Table 4. Unadjusted Predictors of 360-day Survival Characteristic Hazards Ratio 95% Confidence Interval for Hazard Ratio Overall ARF Age Race BSA BMI Days in hospital preoperatively CPB time DT versus BTT HTN DM CRI COPD PVD Ventilated Creatinine Albumin AST ALT Cause (NIDCM versus ICM) ARF acute renal failure; ALT alanine aminotransferase; AST aspartate transaminase; BMI body mass index; BSA body surface area; BTT bridge to transplantation; COPD chronic obstructive pulmonary disease; CPB cardiopulmonary bypass; CRI chronic renal insufficiency; DM diabetes mellitus; DT destination therapy; HTN hypertension; ICM ischemic cardiomyopathy; NIDCM nonidiopathic dilatated cardiomyopathy; PVD peripheral vascular disease. of death included septic shock (20% [1/5]), RV failure (40% [2/5]), stroke (20% [1/5]), and disconnection from the power source (20% [1/5]). Causes of death for the patients in whom renal failure developed were septic shock (25% [2/8]), RV heart failure (38% [3/8]), stroke (25% [2/8]), and bowel perforation (12% [1/8]). Multivariate Analysis Accounting for all the variables that were significant predictors of 360-day mortality in the univariate analysis (Table 4), a multivariate analysis was performed. Postoperative ARF and preoperative CRI were the only statistically significant independent predictors of 360-day survival (Table 5). Comment LVADs continue to stand as an excellent therapeutic option for the growing population of patients with endstage heart disease. The role of these devices is well established as BTT therapy as well as DT [2]. LVAD is proving important in the newly explored role of bridge to candidacy, mostly secondary to the stabilizing and sometimes beneficial effect of circulatory support on end-organ function [7, 17, 18]. With the limited number of donor hearts, predicting outcomes of LVAD is of paramount importance for risk stratification and organ allocation, in particular for patients who are marginally eligible for transplantation [19 22]. The relationship between LVAD and renal function is complex and intricate. Renal dysfunction was shown to be a predictor of poor outcome and death in patients receiving LVADs [7] and is sometimes considered a contraindication for device implantation. Conversely, mechanical circulatory support has proved beneficial for end-organ perfusion and has shown improved renal function in multiple studies [7, 23, 24]. Furthermore, another level of complexity is that function before implantation is not necessarily a strong predictor of ARF after LVAD implantation [7, 24, 25]. In our study, 28 of 100 patients experienced ARF as defined by the RIFLE criteria, a rate of 28% that is comparable to the ARF incidence after LAVD implantation in other studies. The ARF and non-arf groups were comparable with regard to demographics and comorbidities. The mean baseline creatinine level was slightly higher in the group that developed ARF (1.6 mg/dl versus 1.3 mg/dl), but this did not translate into a
6 168 BORGI ET AL Ann Thorac Surg POSTOPERATIVE ARF AFTER LVAD IMPLANTATION 2013;95:163 9 statistically significant difference in the rate of CRI. This is in agreement with the previously described notion that renal dysfunction before implantation may not be the best predictor of postoperative ARF [7, 24, 25]. Another difference between the 2 groups is the higher percentage of patients who were ventilated before implantation in the subgroup of patients in whom ARF developed after implantation (14.3% versus 1.4%), which reflects the sicker or crashing nature of that group. This sicker nature extended to the postoperative stage, with longer ICU stays and overall hospital stays in the ARF versus the non-arf group (18.6 versus 9.5 and 32.4 versus 18.7, respectively). Of the patients in whom renal failure developed, 32% (9/28) proceeded to receive renal replacement therapy (RRT), again a rate similar to that published in the LVAD literature [26]. Of those who required dialysis, 44% (4/9) were free of dialysis within 1 month of implantation. Perhaps the most important finding in this study is the relationship between renal failure after transplantation and mortality, which is shown at 30-day (17.9 % versus 0%), 180-day (28.6% versus 2%) and 360-day (28.6% versus 6.9%) intervals. This relationship may seem intuitive and easily predictable at first, but it acquires more significance in the context of the complex interaction between renal dysfunction before implantation and renal function after implantation. Examining the patients who experienced ARF, we noticed that the vast majority exhibited renal dysfunction in the first few days after implantation. With the association shown between ARF and mortality, postoperative ARF may stand to be the first marker of poor outcome after LVAD implantation. Of note, this association between ARF and mortality seems strongest early on, with 17.9 % mortality at 30 days, which rises to 28.6% at 180 days and subsequently plateaus. This again highlights the importance of ARF as an early marker of mortality in patients receiving LVADs. Looking at the multivariable analysis and adjusting for other confounding variables, postoperative ARF continued to be a strong predictor of mortality with a hazard ratio of Another very interesting point is the difference noted in the rate of RV failure between the ARF and non-arf groups (25% versus 5.6%; p 0.01) and the rate of RVAD placement (17.9% versus 0%). This finding again points to ARF development after implantation as an early marker of poor outcomes that may be due to an underlying dysfunctional right ventricle. According to our hemodynamic data, patients with ARF had higher CVP before LVAD implantation and lower LVEDD before LVAD implantation. This may underline worse RV function that was subclinical before the LVAD implantation. Early placement of an RVAD may be a potential rescue mechanism that deserves to be considered in this particularly sick subgroup. Our study has several limitations. First, this was an observational nonrandomized study and is subject to limitations inherent to any retrospective study. Second, statistical tests were insufficiently powered owing to our relatively small sample size and small percentage of patients in the ARF subgroup. Third, the duration of follow-up is short and long-term outcomes are not defined. Finally, this was a single-institution study and selection bias may be present. In conclusion, in this study we show an association between ARF after LVAD implantation and mortality. This effect on outcome appears to be more significant in the early postoperative period. It also appears to be related to RV failure. One mechanism of rescue may be the early implantation of an RVAD. Finally, the relationship between renal function and LVADs is complex and requires extensive attention. Larger studies are needed to assess and validate the predictors of outcomes and identify the areas of possible beneficial interventions. References 1. American Heart Association: Heart disease and stroke statistics 2007 update. American Heart Association, Dallas, TX, Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001;5;345: Caccamo M, Eckman P, John R. Current state of ventricular assist devices. Curr Heart Fail Rep 2011;8: Forman DE, Butler J, Wang Y, et al. Incidence, predictors and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004;43: Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000;102: Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000;35: Butler J, Carrie Geisberg C, Howser R, et al. Relationship between renal function and left ventricular assist device use. Ann Thorac Surg 2006;81: Kanter KR, Swartz MT, Pennington DG, et al. Renal failure in patients with ventricular assist devices. ASAIO Trans 1987;33: Kaltenmaier B, Pommer W, Kaufmann F, Hennig E, Molzahn M, Hetzer R. Outcome of patients with ventricular assist devices and acute renal failure requiring renal replacement therapy. ASAIO J 2000;46: Khot UM, Mishra M, Yamani MH, et al. Severe renal dysfunction complicating cardiogenic shock is not a contraindication to mechanical support as a bridge to cardiac transplantation. J Am Coll Cardiol 2003;41: Aaronson KD, Patel H, Pagani FD. Patient selection for left ventricular assist device therapy. Ann Thorac Surg 2003;75(6 suppl):s Oz MC, Rose EA, Levin HR. Selection criteria for placement of left ventricular assist devices. Am Heart J 1995;129: Reedy JE, Swartz MT, Termuhlen DF, et al. Bridge to heart transplantation: importance of patient selection. J Heart Transplant 1990;9: Farrar DJ. Preoperative predictors of survival in patients with Thoratec ventricular assist devices as a bridge to heart transplantation: Thoratec Ventricular Assist Device Principal Investigators. J Heart Lung Transplant 1994;13: Sandner SE, Zimpfer D, Zrunek P, et al. Renal function and outcome after continuous flow left ventricular assist device implantation. Ann Thorac Surg 2009;87: Bellomo R, Ronco C, Kellum JA, Mehta RL, Paleversusky P; Acute Dialysis Quality Initiative workgroup. Acute renal failure definition, outcome measures, animal models, fluid therapy and information technology needs: the Second In-
7 Ann Thorac Surg BORGI ET AL 2013;95:163 9 POSTOPERATIVE ARF AFTER LVAD IMPLANTATION ternational Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R Young JB, Rogers JG, Portner PM, et al. Bridge to eligibility: LVAS support in patients with relative contraindications to transplantation (abstract). J Heart Lung Transplant 2005; 24:S Kainuma S, Sakaguchi T, Saito S, et al. Implantation of a Jarvik 2000 left ventricular assist device as a bridge to eligibility for refractory heart failure with renal dysfunction. J Artif Organs 2012;15: Costanzo MR, Augustine S, Bourge RC, et al. Selection and treatment of candidates for heart transplantation. A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation 1995;92: O Connell JB, Bourge RC, Costanzo-Nordin MR, et al. Cardiac transplantation: recipient selection, donor procurement, and medical follow-up. A statement for health professionals from the Committee on Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation 1992;86: Bourge RC, Naftel DC, Costanzo-Nordin MR, et al. Pretransplantation risk factors for death after heart transplantation: a multi institutional study. The Transplant Cardiologists Research Database Group. J Heart Lung Transplant 1993;12: Ostermann ME, Rogers CA, Saeed I, et al. Pre-existing renal failure doubles 30-day mortality after heart transplantation. J Heart Lung Transplant 2004;23: Letsou GV, Myers TJ, Gregoric ID, et al. Continuous axialflow left ventricular assist device (Jarvik 2000) maintains kidney and liver perfusion for up to 6 months. Ann Thorac Surg 2003;76: Sandner SE, Zimpfer D, Zrunek P, et al. Renal function after implantation of continuous versus pulsatile flow left ventricular assist devices. J Heart Lung Transplant 2008;27: Sandner SE, Zimpfer D, Zrunek P, et al. Renal function and outcome after continuous flow left ventricular assist device implantation. Ann Thorac Surg 2009;87: Demirozu ZT, Etheridge WB, Radovancevic R, Frazier OH. Results of HeartMate II left ventricular assist device implantation on renal function in patients requiring post-implant renal replacement therapy. J Heart Lung Transplant 2011;30: INVITED COMMENTARY Acute renal failure (ARF) is a common sequela of left ventricular assist device (LVAD) implantation in patients with end-stage heart failure. The pathophysiologic interaction of cardiac and renal disorders is highly complex. Compromised hemodynamics and deteriorated renal function often create a vicious circle and pose a therapeutic challenge. The mechanical circulatory support of LVAD with pulsatile or nonpulsatile blood flow may render this clinical entity more intricate. Despite important advances in our understanding of this clinical challenge, little is known about the effects of postoperative ARF on the clinical outcome of LVAD implantation. In a retrospective study, Dr Borgi and coworkers [1] analyzed the clinical data for 100 patients undergoing LVAD implantation (HeartMate II or HeartWare) and stratified them based on the postoperative development of ARF defined as decrease in glomerular filtration rate of more than 50% or doubling of serum creatinine level. The results of this study clearly demonstrate the higher mortality rate of patients with postoperative development of ARF not only in the postoperative period, but also at the 180- and 360-day intervals, when comparing to that of patients without postoperative ARF. In the multivariate analysis of various clinical parameters, postoperative ARF and preoperative chronic renal insufficiency were the only statistically significant independent predictors of 360-day survival. Moreover, postoperative ARF was also associated with worse right ventricular function before LVAD implantation and a higher incidence of postoperative right ventricular failure and requirement for implantation of right ventricular assist device. This article elucidates the predictive value of postoperative ARF as an early marker of a poor clinical outcome of LVAD implantation. It also emphasizes the importance of optimal clinical management and early intervention of right ventricular failure in this very sick and desperate patient population. I believe that this article will broaden the discussion and contribute further evidence regarding this highly relevant clinical topic. Ruoyu Zhang, MD Department of Cardiac, Thoracic Transplantation and Vascular Surgery Hannover Medical School Carl-Neuberg Str Hannover, Germany zhang.ruoyu@mh-hannover.de Reference 1. Borgi J, Tsiouris A, Hodari A, Cogan CM, Paone G, Morgan JA. Significance of postoperative acute renal failure after continuous-flow left ventricular assist device implantation. Ann Thorac Surg 2013;95: by The Society of Thoracic Surgeons /$36.00 Published by Elsevier Inc
Age and Outcome After Continuous-Flow Left Ventricular Assist Device Implantation as Bridge to Transplantation
Age and Outcome After Continuous-Flow Left Ventricular Assist Device Implantation as Bridge to Transplantation Sigrid E. Sandner, MD, a Daniel Zimpfer, MD, a Philipp Zrunek, a Angela Rajek, MD, b Heinrich
More informationConcomitant Aortic Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis
Concomitant Aortic Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis April 11, 2014 Jason O. Robertson, M.D., M.S.; David C. Naftel, Ph.D., Sunil
More informationReversal of secondary pulmonary hypertension by axial and pulsatile mechanical circulatory support
http://www.jhltonline.org Reversal of secondary pulmonary hypertension by axial and pulsatile mechanical circulatory support Guillermo Torre-Amione, MD, PhD, a Robert E. Southard, MD, b Matthias M. Loebe,
More informationA Validated Practical Risk Score to Predict the Need for RVAD after Continuous-flow LVAD
A Validated Practical Risk Score to Predict the Need for RVAD after Continuous-flow LVAD SK Singh MD MSc, DK Pujara MBBS, J Anand MD, WE Cohn MD, OH Frazier MD, HR Mallidi MD Division of Transplant & Assist
More informationMulticenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) Long Term Outcomes
Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with (MOMENTUM 3) Long Term Outcomes Mandeep R. Mehra, MD, Daniel J. Goldstein, MD, Nir Uriel, MD, Joseph
More informationSevere Renal Dysfunction Complicating Cardiogenic Shock Is Not a Contraindication to Mechanical Support as a Bridge to Cardiac Transplantation
Journal of the American College of Cardiology Vol. 41, No. 3, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02823-1
More informationJournal of the American College of Cardiology Vol. 60, No. 1, by the American College of Cardiology Foundation ISSN /$36.
Journal of the American College of Cardiology Vol. 60, No. 1, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.02.031
More informationUpdate on Mechanical Circulatory Support. AATS May 5, 2010 Toronto, ON Canada
Update on Mechanical Circulatory Support AATS May 5, 2010 Toronto, ON Canada Disclosures NONE Emergency Circulatory Support ECMO Tandem Heart Impella Assessment Cardiac Function Pulmonary function Valvular
More informationRamani GV et al. Mayo Clin Proc 2010;85:180-95
THERAPIES FOR ADVANCED HEART FAILURE: WHEN TO REFER Navin Rajagopalan, MD Assistant Professor of Medicine University of Kentucky Director, Congestive Heart Failure Medical Director of Cardiac Transplantation
More informationBridge to Heart Transplantation
Bridge to Heart Transplantation Ulf Kjellman MD, PhD Senior Consultant Surgeon Heart Centre KFSH&RC 1 Disclosure Appointed for Proctorship by Thoratec/St.Jude/Abbott 2 To run a full overall covering transplant
More informationDo Posttransplant Outcomes Differ in Heart Transplant Recipients Bridged With Continuous and Pulsatile Flow Left Ventricular Assist Devices?
Do Posttransplant Outcomes Differ in Heart Transplant Recipients Bridged With Continuous and Pulsatile Flow Left Ventricular Assist Devices? Kimberly N. Hong, MHSA, Alexander Iribarne, MD, MS, Jonathan
More informationThe Who, How and When of Advanced Heart Failure Therapies. Disclosures. What is Advanced Heart Failure?
The Who, How and When of Advanced Heart Failure Therapies 9 th Annual Dartmouth Conference on Advances in Heart Failure Therapies Dartmouth-Hitchcock Medical Center Lebanon, NH May 20, 2013 Joseph G. Rogers,
More informationRight Ventricular Failure: Prediction, Prevention and Treatment
Right Ventricular Failure: Prediction, Prevention and Treatment 3 rd European Training Symposium for Heart Failure Cardiologists and Cardiac Surgeons University Hospital Bern June 24-25, 2016 Disclosures:
More informationSerial Changes in Renal Function as a Prognostic Indicator in Advanced Heart Failure Patients With Left Ventricular Assist System
ADULT CARDIAC Serial Changes in Renal Function as a Prognostic Indicator in Advanced Heart Failure Patients With Left Ventricular Assist System Yoshio Iwashima, MD, PhD, Masanobu Yanase, MD, PhD, Takeshi
More informationLVAD Complications, Recovery
LVAD Complications, Recovery Abbas Ardehali, M.D., F.A.C.S. Professor of Surgery and Medicine, Division of Cardiac Surgery William E. Connor Chair in Cardiothoracic Transplantation Director, UCLA Heart,
More informationDerivation and Validation of a Novel Right-Sided Heart Failure Model After Implantation of Continuous Flow Left Ventricular Assist Devices: the EUROMACS-RHF Risk Score Osama I.I. Soliman, MD, PhD, FACC,
More informationVentricular Assist Devices for Permanent Therapy: Current Status and Future
Ventricular Assist Devices for Permanent Therapy: Current Status and Future Prospects Francis D. Pagani MD PhD Professor of Cardiac Surgery University of Michigan April 28 th, 2012 Disclosures NHLBI and
More informationVentricular Assist Device Implant in the Elderly Is Associated With Increased, but Respectable Risk: A Multi-Institutional Study
Ventricular Assist Device Implant in the Elderly Is Associated With Increased, but Respectable Risk: A Multi-Institutional Study Pavan Atluri, MD, Andrew B. Goldstone, MD, Dale M. Kobrin, BA, Jeffrey E.
More informationLeft ventricular assist devices (LVAD) have been demonstrated
Is Severe Right Ventricular Failure in Left Ventricular Assist Device Recipients a Risk Factor for Unsuccessful Bridging to Transplant and Post-Transplant Mortality Jeffrey A. Morgan, MD, Ranjit John,
More informationLeft Ventricular Assist Devices (LVADs): Overview and Future Directions
Left Ventricular Assist Devices (LVADs): Overview and Future Directions FATIMA KARAKI, M.D. PGY-3, DEPARTMENT OF MEDICINE WASHINGTON UNIVERSITY IN ST. LOUIS ST. LOUIS, MISSOURI, USA St. Louis, Missouri,
More informationA Fully Magnetically Levitated Left Ventricular Assist Device. Final Report of the MOMENTUM 3 Trial
A Fully Magnetically Levitated Left Ventricular Assist Device Final Report of the MOMENTUM 3 Trial Mandeep R. Mehra, MD, Nir Uriel, MD, Joseph C. Cleveland, Jr., MD, Daniel J. Goldstein, MD, National Principal
More informationPredictor of Early Mortality for Severe Heart Failure Patients With Left Ventricular Assist Device Implantation
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp ORIGINAL ARTICLE Cardiovascular Surgery Predictor of Early Mortality for Severe Heart Failure Patients With
More informationMEDICAL POLICY SUBJECT: VENTRICULAR ASSIST DEVICES
MEDICAL POLICY PAGE: 1 OF: 7 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationEffect of Pre-LVAD PVR on Heart Transplant Outcome
AATS 2015, VAD/ECMO Session Effect of Pre-LVAD PVR on Heart Transplant Outcome Masaki Tsukashita, MD, PhD, Hiroo Takayama, MD, PhD, Koji Takeda, MD, PhD, Jiho Han, BS, Sowmyashree Sreekanth, BS, Lauren
More informationORIGINAL ARTICLE. Alexander M. Bernhardt a, *, Theo M.M.H. De By b, Hermann Reichenspurner a and Tobias Deuse a. Abstract INTRODUCTION
European Journal of Cardio-Thoracic Surgery 48 (2015) 158 162 doi:10.1093/ejcts/ezu406 Advance Access publication 29 October 2014 ORIGINAL ARTICLE Cite this article as: Bernhardt AM, De By TMMH, Reichenspurner
More informationEvaluation of the Right Ventricle in Candidates for Right Ventricular Assist Device Implantation.
Evaluation of the Right Ventricle in Candidates for Right Ventricular Assist Device Implantation. Evaluation of RVAD Function. Ioannis A Paraskevaidis Attikon University Hospital Historical Perspective
More informationWhat are the indications for Tricuspid valve repair during LVAD Implant RANJIT JOHN, MD UNIVERSITY OF MINNESOTA
What are the indications for Tricuspid valve repair during LVAD Implant RANJIT JOHN, MD UNIVERSITY OF MINNESOTA Contraindications for LVAD Lack of social support system Nonreversible end organ failure
More informationRenal Function and Outcome After Continuous Flow Left Ventricular Assist Device Implantation
Renal Function and Outcome After Continuous Flow Left Ventricular Assist Device Implantation Sigrid E. Sandner, MD, Daniel Zimpfer, MD, Philipp Zrunek, Angela Rajek, MD, Heinrich Schima, PhD, Daniela Dunkler,
More informationHeart-lung transplantation: adult indications and outcomes
Brief Report Heart-lung transplantation: adult indications and outcomes Yoshiya Toyoda, Yasuhiro Toyoda 2 Temple University, USA; 2 University of Pittsburgh, USA Correspondence to: Yoshiya Toyoda, MD,
More informationAdvances in Advanced Heart Failure Therapies. Disclosures. Management Algorithm for Patients in Cardiogenic Shock
Advances in Advanced Heart Failure Therapies 9 th Annual Dartmouth Conference on Advances in Heart Failure Therapies Dartmouth-Hitchcock Medical Center May 20, 2013 Joseph G. Rogers, M.D. Associate Professor
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Cardiogenic Shock Mechanical Support Eulàlia Roig FESC Heart Failure and HT Unit Hospital Sant Pau - UAB Barcelona. Spain No conflics of interest Mechanical Circulatory
More informationPediatric Mechanical Circulatory Support (MCS)
Pediatric Mechanical Circulatory Support (MCS) Ivan Wilmot, MD Heart Failure, Transplant, MCS Assistant Professor The Heart Institute Cincinnati Children s Hospital Medical Center The University of Cincinnati
More informationOutcomes and Predictors of Early Mortality After Continuous-Flow Left Ventricular Assist Device Implantation as a Bridge to Transplantation
ASAIO Journal 2014 Outcomes and Predictors of Early Mortality After Continuous-Flow Left Ventricular Assist Device Implantation as a Bridge to Transplantation Anton Sabashnikov,* Prashant N. Mohite,* Bartlomiej
More informationThe HeartMate II is a new continuous-flow left ventricular. Heart Failure
Heart Failure Renal and Hepatic Function Improve in Advanced Heart Failure Patients During Continuous-Flow Support With the HeartMate II Left Ventricular Assist Device Stuart D. Russell, MD; Joseph G.
More informationPredictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
More informationNone. Declaration of conflict of interest
None Declaration of conflict of interest New Long Term Circulatory Support Technology and Treatment Strategies Stephen Westaby Oxford, UK Cardiac Transplantation: Facts from the UNOS Database Median survival
More informationMechanical assist patient selection, device selection, and outcomes
Mechanical assist patient selection, device selection, and outcomes Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine
More informationSurgical Options for Advanced Heart Failure
Surgical Options for Advanced Heart Failure Benjamin Medalion, MD Director, Transplantation and Heart Failure Surgery Department of Cardiothoracic Surgery Rabin Medical Center, Beilinson Hospital Heart
More informationMinimally Invasive Insertion of HVAD
Minimally Invasive Insertion of HVAD Simon Maltais, MD PhD Vice-Chair of Clinical Practice Director of MCS Program Department of Cardiovascular Surgery Mayo Clinic, Rochester, MN AATS MCS 2018, Houston
More informationTemporary right ventricular mechanical circulatory support for the management of right ventricular failure in critically ill patients
Perioperative Management Aissaoui et al Temporary right ventricular mechanical circulatory support for the management of right ventricular failure in critically ill patients Nadia Aissaoui, MD, a,b Michiel
More informationModel for end-stage liver disease predicts right ventricular failure in patients with left ventricular assist devices
J Artif Organs (2016) 19:21 28 DOI 10.1007/s10047-015-0853-x ORIGINAL ARTICLE Artificial Heart (Clinical) Model for end-stage liver disease predicts right ventricular failure in patients with left ventricular
More informationRisk Factors for Adverse Outcome after HeartMate II Jennifer Cowger, MD, MS St. Vincent Heart Center of Indiana
Risk Factors for Adverse Outcome after HeartMate II Jennifer Cowger, MD, MS St. Vincent Heart Center of Indiana Advanced Heart Failure, Transplant, & Mechanical Circulatory Support Relevant Financial Relationship
More informationStatus of Implantable VADs
Status of Implantable VADs John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine Division of Cardiac Surgery The Johns Hopkins Medical Institutions Conflict of Interest Statement
More informationContinuous Flow Left Ventricular Assist Device Outcomes in Commercial Use Compared With the Prior Clinical Trial
Continuous Flow Left Ventricular Assist Device Outcomes in Commercial Use Compared With the Prior Clinical Trial Ranjit John, MD, Yoshifumi Naka, MD, Nicholas G. Smedira, MD, Randall Starling, MD, MPH,
More informationDEMYSTIFYING VADs. Nicolle Choquette RN MN Athabasca University
DEMYSTIFYING VADs Nicolle Choquette RN MN Athabasca University Objectives odefine o Heart Failure o VAD o o o o Post Operative Complications Acute Long Term Nursing Interventions What is Heart Failure?
More informationAortic Insufficiency: How Often Does It Occur and When To Treat
Aortic Insufficiency: How Often Does It Occur and When To Treat Simon Maltais, MD PhD Vice-Chair of Clinical Practice Director of MCS Program Department of Cardiovascular Surgery Mayo Clinic, Rochester,
More informationThe Effect of Ventricular Assist Devices on Post-Transplant Mortality
Journal of the American College of Cardiology Vol. 53, No. 3, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.08.070
More informationDo we really need an Artificial Heart? No!! John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine
Do we really need an Artificial Heart? No!! John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine Division of Cardiac Surgery The Johns Hopkins Medical Institutions Conflict
More informationDoes Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement?
Original Article Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement? Hiroaki Sakamoto, MD, PhD, and Yasunori Watanabe, MD, PhD Background: Recently, some articles
More informationReadmissions After Ventricular Assist Device: Etiologies, Patterns, and Days Out of Hospital
Readmissions After Ventricular Assist Device: Etiologies, Patterns, and Days Out of Hospital Stephen J. Forest, MD, Ricardo Bello, MD, PhD, Patricia Friedmann, MS, Danielle Casazza, RN, Cecilia Nucci,
More informationManagement of Cardiogenic Shock. Dr Stephen Pettit, Consultant Cardiologist
Dr Stephen Pettit, Consultant Cardiologist Cardiogenic shock Management of Cardiogenic Shock Outline Definition, INTERMACS classification Medical management of cardiogenic shock PA catheters and haemodynamic
More informationPredicting Survival in Patients Receiving Continuous Flow Left Ventricular Assist Devices
Journal of the American College of Cardiology Vol. 61, No. 3, 2013 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.055
More informationDisclosures. No disclosures to report
Disclosures No disclosures to report Update on MOMENTUM 3 Trial: The Final Word? Francis D. Pagani MD PhD Otto Gago MD Professor of Cardiac Surgery University of Michigan Ann Arbor, Michigan, USA LVAD
More informationImplantable Ventricular Assist Devices and Total Artificial Hearts. Policy Specific Section: June 13, 1997 March 29, 2013
Medical Policy Implantable Ventricular Assist Devices and Total Artificial Hearts Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Surgery Original Policy Date: Effective
More informationThe Development of Aortic Insufficiency in Continuous-Flow Left Ventricular Assist Device Supported Patients
The Development of Aortic Insufficiency in Continuous-Flow Left Ventricular Assist Device Supported Patients Ashim Aggarwal, MD, MRCP, Rashmi Raghuvir, MD, Paula Eryazici, MD, Gregory Macaluso, MD, Priya
More informationUnderstanding the Pediatric Ventricular Assist Device
Understanding the Pediatric Ventricular Assist Device W. James Parks, MSc., MD Pediatric Cardiologist Assistant Professor of Pediatrics and Radiology Children s Healthcare of Atlanta Sibley Heart Center
More informationMechanical Circulatory Support in the Management of Heart Failure
Mechanical Circulatory Support in the Management of Heart Failure Feras Bader, MD, MS, FACC Associate Professor of Medicine Director, Heart Failure and Transplant Cleveland Clinic Abu Dhabi Chairman, Heart
More informationHow effective are continuous flow left ventricular assist devices in lowering high pulmonary artery pressures in heart transplant candidates?
ORIGINAL ARTICLE Cardiology Journal 2012, Vol. 19, No. 2, pp. 153 158 10.5603/CJ.2012.0027 Copyright 2012 Via Medica ISSN 1897 5593 How effective are continuous flow left ventricular assist devices in
More informationFifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients
http://www.jhltonline.org SPECIAL FEATURE Fifth INTERMACS annual report: Risk factor analysis from more than 6, mechanical circulatory support patients James K. Kirklin, MD, a David C. Naftel, PhD, a Robert
More informationUniversity of Groningen. Acute kidney injury after cardiac surgery Loef, Berthus Gerard
University of Groningen Acute kidney injury after cardiac surgery Loef, Berthus Gerard IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it.
More informationHow to mend a broken heart: transplantation or LVAD?
SCDU DI CARDIOCHIRURGIA Università degli Studi di Torino Ospedale S. Giovanni Battista Direttore: Prof. Mauro Rinaldi How to mend a broken heart: transplantation or LVAD? Massimo Boffini Mauro Rinaldi
More informationMechanical Support in the Failing Fontan-Kreutzer
Mechanical Support in the Failing Fontan-Kreutzer Stephanie Fuller MD, MS Thomas L. Spray Endowed Chair in Congenital Heart Surgery Associate Professor, The Perelman School of Medicine at the University
More informationClinical Experience With HeartWare Left Ventricular Assist Device in Patients With End-Stage Heart Failure
ADULT CARDIAC Clinical Experience With HeartWare Left Ventricular Assist Device in Patients With End-Stage Heart Failure Aron Frederik Popov, MD, Morteza Tavakkoli Hosseini, MD, Bartlomiej Zych, MD, Prashant
More informationPercutaneous Cardiopulmonary Support after Acute Myocardial Infarction at the Left Main Trunk
Original Article Percutaneous Cardiopulmonary Support after Acute Myocardial Infarction at the Left Main Trunk Takashi Yamauchi, MD, PhD, 1 Takafumi Masai, MD, PhD, 1 Koji Takeda, MD, 1 Satoshi Kainuma,
More informationFirst Experiences With the HeartWare Ventricular Assist System in Children
First Experiences With the HeartWare Ventricular Assist System in Children Oliver Miera, MD, Evgenij V. Potapov, MD, PhD, Matthias Redlin, MD, Alexander Stepanenko, MD, Felix Berger, MD, PhD, Roland Hetzer,
More informationHeart Transplantation is Dead
Heart Transplantation is Dead Alternatives to Transplantation in Heart Failure Sagar Damle, MD University of Colorado Health Sciences Center Grand Rounds September 8, 2008 Outline Why is there a debate?
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter
More informationImpact of Renal Function Before Mechanical Circulatory Support on Posttransplant Renal Outcomes
Impact of Renal Function Before Mechanical Circulatory Support on Posttransplant Renal Outcomes Madhurmeet Singh, DO, Michael Shullo, PharmD, Robert L. Kormos, MD, Kathleen Lockard, RN, Rachelle Zomak,
More informationInitial Experience of Conversion of Toyobo Paracorporeal Left Ventricular Assist Device to DuraHeart Left Ventricular Assist Device
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Advance Publication by J-STAGE Initial Experience of Conversion of Toyobo Paracorporeal Left Ventricular
More informationLessons learned from ENDURANCE, ROADMAP, MedaMACS, and how to go forward?
Lessons learned from ENDURANCE, ROADMAP, MedaMACS, and how to go forward? Mark S. Slaughter, MD Professor and Chair Department of Cardiovascular and Thoracic Surgery University of Louisville What could
More informationAllinaHealthSystem 1
: Definition End-organ hypoperfusion secondary to cardiac failure Venoarterial ECMO: Patient Selection Michael A. Samara, MD FACC Advanced Heart Failure, Cardiac Transplant & Mechanical Circulatory Support
More informationPredicting Major Outcomes after MCSD Implant. Risk Factors for Death, Transplant, and Recovery. James Kirklin, MD David Naftel, PhD
Predicting Major Outcomes after MCSD Implant Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD 1 I have no financial disclosures (I am the Principle Investigator for
More informationHeartWare ADVANCE Bridge to Transplant Trial and Continued Access Protocol Update
HeartWare ADVANCE Bridge to Transplant Trial and Continued Access Protocol Update Mark S. Slaughter, MD University of Louisville, KY, USA HeartWare Users Meeting 29 October 2012 Barcelona, Spain HEARTWARE,
More informationHow do Readmissions Impact Survival among Patients with Continuous-Flow Left Ventricular Assist Devices? Findings from INTERMACS
How do Readmissions Impact Survival among Patients with Continuous-Flow Left Ventricular Assist Devices? Findings from INTERMACS Rey P. Vivo, MD 1 ; Selim R. Krim, MD 2 ; Jerry D. Estep, MD 3 ; Wissam
More informationRepeated Ramp Tests on Stable LVAD Patients Reveal Patient-Specific Hemodynamic Fingerprint
ASAIO Journal 2017 Adult Circulatory Support Repeated Ramp Tests on Stable LVAD Patients Reveal Patient-Specific Hemodynamic Fingerprint TERUHIKO IMAMURA,* DANIEL BURKHOFF, DANIEL RODGERS,* SIRTAZ ADATYA,*
More informationWHEN TO REFER FOR ADVANCED HEART FAILURE THERAPIES
WHEN TO REFER FOR ADVANCED HEART FAILURE THERAPIES Mrudula R Munagala, M.D., FACC CO- Director Heart Failure & Circulatory Support Program OklahomaHeart.com Heart Failure Prevalence Heart Failure affects
More informationMechanical Cardiac Support in Acute Heart Failure. Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research
Mechanical Cardiac Support in Acute Heart Failure Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research Disclosures Research Support and/or Consulting NHLBI Amgen Cytokinetics
More informationLVADs as a long term or destination therapy for the advanced heart failure
LVADs as a long term or destination therapy for the advanced heart failure Prof. Davor Miličić, MD, PhD University of Zagreb School of Medicine Department of Cardiovascular Diseases University Hospital
More informationEvaluation of Native Left Ventricular Function During Mechanical Circulatory Support.: Theoretical Basis and Clinical Limitations
Review Evaluation of Native Left Ventricular Function During Mechanical Circulatory Support.: Theoretical Basis and Clinical Limitations Tohru Sakamoto, MD, PhD Left ventricular function on patients with
More informationSurvival analysis and postoperative complications after ventricular assist device implantation; prognostic value of INTERMACS scale.
Research Article http://www.alliedacademies.org/annals-of-cardiovascular-and-thoracic-surgery/ Survival analysis and postoperative complications after ventricular assist device implantation; prognostic
More informationManagement of Acute Shock and Right Ventricular Failure
Management of Acute Shock and Right Ventricular Failure Nader Moazami, MD Department of Thoracic and Cardiovascular Surgery and Biomedical Engineering, Cleveland Clinic NONE Disclosures CARDIOGENIC SHOCK
More informationCHANGING THE WAY HEART FAILURE IS TREATED. VAD Therapy
CHANGING THE WAY HEART FAILURE IS TREATED VAD Therapy VAD THERAPY IS BECOMING AN ESSENTIAL PART OF HEART FAILURE PROGRAMS AROUND THE WORLD. Patients with advanced heart failure experience an impaired quality
More informationModern Left Ventricular Assist Devices (LVAD) : An Intro, Complications, and Emergencies
Modern Left Ventricular Assist Devices (LVAD) : An Intro, Complications, and Emergencies ERIC T. ROME D.O. HEART FAILURE, MECHANICAL ASSISTANCE AND TRANSPLANTATION CVI Left Ventricular Assist Device An
More informationModerate TR Should be Repaired at the Time of LVAD Con. James Kirklin MD
Moderate TR Should be Repaired at the Time of LVAD Con James Kirklin MD Disclosure: I am Director of the Data Coordinating Center for the INTERMACS project and receive support through an Institutional
More informationEACTS Adult Cardiac Database
EACTS Adult Cardiac Database Quality Improvement Programme List of changes to Version 2.0, 13 th Dec 2018, compared to version 1.0, 1 st May 2014. INTRODUCTORY NOTES This document s purpose is to list
More informationVentricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation
Ventricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation Objectives Current rationale behind use of MCS Patient Selection Earlier?
More informationAge and Preoperative Total Bilirubin Level Can Stratify Prognosis After Extracorporeal Pulsatile Left Ventricular Assist Device Implantation
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp ORIGINAL ARTICLE Cardiovascular Surgery Age and Preoperative Total Bilirubin Level Can Stratify Prognosis
More informationBody Mass Index and Outcomes After Left Ventricular Assist Device Placement
Body Mass Index and Outcomes After Left Ventricular Assist Device Placement Javed Butler, MD, MPH, Renee Howser, RN, MSN, Peer M. Portner, PhD, and Richard N. Pierson III, MD Cardiology Division, Center
More informationVAD come Destination therapy nell adulto con Scompenso Cardiaco
VAD come Destination therapy nell adulto con Scompenso Cardiaco Francesco Santini Division of Cardiac Surgery, IRCCS San Martino IST University of Genova Medical School, Italy Heart Transplantation is
More informationArtificial Heart Program
Artificial Heart Program Provider Review: General VAD Overview Indications for VAD Bridge to transplant (BTT) historically most common (~80%) allow rehab from severe CHF while awaiting donor Bridge to
More information3/23/2018. Complications of VAD Therapy: Arrhythmias. Disclosures. Agenda. I have no relevant disclosures
March 23, 2018 Complications of VAD Therapy: Arrhythmias Sandeep M. Jani, MD, MPH Associate Directory of Advanced Heart Failure and Population Health MedStar Heart and Vascular Institute - Baltimore Sandeep
More informationAcute Circulatory Support Should We or Shouldn t We?
Acute Circulatory Support Should We or Shouldn t We? Navin K. Kapur, MD, FACC, FSCAI Assistant Professor, Division of Cardiology Director, Acute Circulatory Support Program Director, Interventional Research
More informationWhat has INTERMACS Taught Us about Patient Outcomes with Durable MCS? James K. Kirklin, MD
What has INTERMACS Taught Us about Patient Outcomes with Durable MCS? James K. Kirklin, MD Disclosure: I am Director of the Data Coordinating Center for the INTERMACS project and receive support through
More informationHeart Transplant vs Left Ventricular Assist Device in Heart Transplant-Eligible Patients
Heart Transplant vs Left Ventricular Assist Device in Heart Transplant-Eligible Patients Matthew L. Williams, MD, Jaimin R. Trivedi, MD, MPH, Kelly C. McCants, MD, Sumanth D. Prabhu, MD, Emma J. Birks,
More informationComplications of VAD therapy - RV failure
Complications of VAD therapy - RV failure Nana Afari-Armah, MD Advanced heart failure and transplant cardiology Temple University Hospital 3/24/18 Goals Understand the role of the right ventricle in LVAD
More informationVentricular Assisting Devices in the Cathlab. Unrestricted
Ventricular Assisting Devices in the Cathlab Unrestricted What is a VAD? A single system device that is surgically attached to the left ventricle of the heart and to the aorta for left ventricular support
More informationPediatric Mechanical Circulatory Support - What to Use
Pediatric Mechanical Circulatory Support - What to Use Ronald K. Woods, MD, PhD Associate Professor Medical College of Wisconsin Pediatric Cardiothoracic Surgery Children s Hospital of Wisconsin Disclosure
More informationDestination Therapy SO MUCH DATA IN SUCH A SMALL DEVICE. HeartWare HVAD System The ONLY intrapericardial VAD approved for DT.
DT Destination Therapy SO MUCH DATA IN SUCH A SMALL DEVICE. HeartWare HVAD System The ONLY intrapericardial VAD approved for DT. ONLY WE HAVE THIS BREADTH OF CLINICAL EVIDENCE TO SUPPORT DESTINATION THERAPY.
More informationCorrective Surgery in Severe Heart Failure. Jon Enlow, D.O., FACS Cardiothoracic Surgeon Riverside Methodist Hospital, Ohiohealth Columbus, Ohio
Corrective Surgery in Severe Heart Failure Jon Enlow, D.O., FACS Cardiothoracic Surgeon Riverside Methodist Hospital, Ohiohealth Columbus, Ohio Session Objectives 1.) Identify which patients with severe
More informationSurgery and device intervention for the elderly with heart failure: assessing the need. Devices and Technology for heart failure in 2011
Surgery and device intervention for the elderly with heart failure: assessing the need Devices and Technology for heart failure in 2011 Assessing cardiovascular function / prognosis (in the elderly): composite
More information